Does the media refer more to EYPT or MASS?

In the previous week, 908 Devices had 3 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for 908 Devices and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat 908 Devices' score of 0.29 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 908 Devices 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, MASS or TRNS?

908 Devices has higher earnings, but lower revenue than Transcat. 908 Devices is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 908 Devices $56.20M 5.39 $19.49M -$1.00 N/A Transcat $331.88M 2.48 $5.38M $0.58 151.79

Is MASS or TRNS more profitable?

Transcat has a net margin of 1.62% compared to 908 Devices' net margin of -62.40%. Transcat's return on equity of 5.84% beat 908 Devices' return on equity. Company Net Margins Return on Equity Return on Assets 908 Devices -62.40% -14.03% -10.40% Transcat 1.62% 5.84% 3.78%

Does the media refer more to MASS or TRNS?

In the previous week, 908 Devices had 3 more articles in the media than Transcat. MarketBeat recorded 5 mentions for 908 Devices and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat 908 Devices' score of 0.29 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MASS or CTKB?

In the previous week, 908 Devices had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for 908 Devices and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat 908 Devices' score of 0.29 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MASS or LAB?

In the previous week, 908 Devices and 908 Devices both had 5 articles in the media. Standard BioTools' average media sentiment score of 0.58 beat 908 Devices' score of 0.29 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

908 Devices (MASS) Competitors

$8.01 +0.02 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$8.02 +0.01 (+0.12%)

As of 04:10 PM Eastern

Compare

MASS vs. EYPT, TRNS, FEIM, CTKB, and LAB

Should you buy 908 Devices stock or one of its competitors? MarketBeat compares 908 Devices with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 908 Devices include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), and Standard BioTools (LAB). These companies are all part of the "measuring and control equipment" industry.

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Eyepoint Pharmaceuticals currently has a consensus price target of $31.80, suggesting a potential upside of 157.91%. 908 Devices has a consensus price target of $12.00, suggesting a potential upside of 49.81%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

908 Devices has higher revenue and earnings than Eyepoint Pharmaceuticals. 908 Devices is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	32.95	-$231.96M	-$3.50	N/A
908 Devices	$56.20M	5.39	$19.49M	-$1.00	N/A

In the previous week, 908 Devices had 3 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for 908 Devices and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat 908 Devices' score of 0.29 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
908 Devices	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 28.2% of 908 Devices shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eyepoint Pharmaceuticals has a beta of 1.72, indicating that its stock price is 72% more volatile than the broader market. Comparatively, 908 Devices has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

908 Devices has a net margin of -62.40% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. 908 Devices' return on equity of -14.03% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
908 Devices	-62.40%	-14.03%	-10.40%

Summary

Eyepoint Pharmaceuticals beats 908 Devices on 9 of the 17 factors compared between the two stocks.

How does 908 Devices compare to Transcat?

908 Devices (NASDAQ:MASS) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 28.2% of 908 Devices shares are held by insiders. Comparatively, 2.8% of Transcat shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Transcat has a net margin of 1.62% compared to 908 Devices' net margin of -62.40%. Transcat's return on equity of 5.84% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Transcat	1.62%	5.84%	3.78%

908 Devices currently has a consensus target price of $12.00, suggesting a potential upside of 49.81%. Transcat has a consensus target price of $105.33, suggesting a potential upside of 19.64%. Given 908 Devices' higher probable upside, equities analysts clearly believe 908 Devices is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

908 Devices has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Transcat has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

908 Devices has higher earnings, but lower revenue than Transcat. 908 Devices is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	5.39	$19.49M	-$1.00	N/A
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79

In the previous week, 908 Devices had 3 more articles in the media than Transcat. MarketBeat recorded 5 mentions for 908 Devices and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat 908 Devices' score of 0.29 indicating that Transcat is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Transcat beats 908 Devices on 12 of the 17 factors compared between the two stocks.

How does 908 Devices compare to Frequency Electronics?

908 Devices (NASDAQ:MASS) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

908 Devices presently has a consensus price target of $12.00, indicating a potential upside of 49.81%. Frequency Electronics has a consensus price target of $43.67, indicating a potential downside of 34.46%. Given 908 Devices' higher possible upside, research analysts clearly believe 908 Devices is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

908 Devices has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Frequency Electronics has a net margin of 10.78% compared to 908 Devices' net margin of -62.40%. Frequency Electronics' return on equity of 12.69% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Frequency Electronics	10.78%	12.69%	7.84%

In the previous week, 908 Devices had 4 more articles in the media than Frequency Electronics. MarketBeat recorded 5 mentions for 908 Devices and 1 mentions for Frequency Electronics. Frequency Electronics' average media sentiment score of 0.93 beat 908 Devices' score of 0.29 indicating that Frequency Electronics is being referred to more favorably in the news media.

Company	Overall Sentiment
908 Devices	Neutral
Frequency Electronics	Positive

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Frequency Electronics has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	5.39	$19.49M	-$1.00	N/A
Frequency Electronics	$69.81M	9.39	$23.69M	$0.75	88.84

Summary

Frequency Electronics beats 908 Devices on 12 of the 16 factors compared between the two stocks.

How does 908 Devices compare to Cytek Biosciences?

908 Devices (NASDAQ:MASS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

In the previous week, 908 Devices had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for 908 Devices and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat 908 Devices' score of 0.29 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a net margin of -36.25% compared to 908 Devices' net margin of -62.40%. Cytek Biosciences' return on equity of -10.07% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

908 Devices has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

908 Devices presently has a consensus target price of $12.00, indicating a potential upside of 49.81%. Cytek Biosciences has a consensus target price of $5.69, indicating a potential upside of 40.43%. Given 908 Devices' higher possible upside, equities analysts plainly believe 908 Devices is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

908 Devices has higher earnings, but lower revenue than Cytek Biosciences. 908 Devices is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	5.39	$19.49M	-$1.00	N/A
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A

Summary

Cytek Biosciences beats 908 Devices on 10 of the 16 factors compared between the two stocks.

How does 908 Devices compare to Standard BioTools?

908 Devices (NASDAQ:MASS) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

908 Devices has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

908 Devices has higher earnings, but lower revenue than Standard BioTools. 908 Devices is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	5.39	$19.49M	-$1.00	N/A
Standard BioTools	$85.33M	4.03	-$74.90M	$0.20	4.41

In the previous week, 908 Devices and 908 Devices both had 5 articles in the media. Standard BioTools' average media sentiment score of 0.58 beat 908 Devices' score of 0.29 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

908 Devices presently has a consensus target price of $12.00, indicating a potential upside of 49.81%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 53.22%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 26.8% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Standard BioTools has a net margin of 73.46% compared to 908 Devices' net margin of -62.40%. Standard BioTools' return on equity of -8.18% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Standard BioTools	73.46%	-8.18%	-6.43%

Summary

Standard BioTools beats 908 Devices on 9 of the 15 factors compared between the two stocks.

Get 908 Devices News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MASS vs. The Competition

Export

Metric	908 Devices	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$302.13M	$7.42B	$6.50B	$11.95B
Dividend Yield	N/A	1.19%	2.67%	5.61%
P/E Ratio	-8.01	38.62	20.85	21.87
Price / Sales	5.39	73.08	500.87	105.21
Price / Cash	N/A	25.48	43.05	54.72
Price / Book	2.02	6.93	10.43	6.70
Net Income	$19.49M	$159.22M	$3.56B	$337.26M
7 Day Performance	-7.51%	-1.91%	-1.39%	-1.41%
1 Month Performance	-1.96%	3.26%	0.86%	1.15%
1 Year Performance	12.82%	-2.82%	19.42%	22.61%

908 Devices Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MASS 908 Devices	2.5092 of 5 stars	$8.01 +0.3%	$12.00 +49.8%	+14.5%	$302.13M	$56.20M	N/A	60
EYPT Eyepoint Pharmaceuticals	2.9241 of 5 stars	$12.51 -7.8%	$31.80 +154.1%	+31.8%	$1.14B	$31.37M	N/A	120
TRNS Transcat	3.4882 of 5 stars	$88.13 +4.3%	$105.33 +19.5%	+17.4%	$789.48M	$331.88M	153.74	1,413	Positive News High Trading Volume
FEIM Frequency Electronics	1.5797 of 5 stars	$72.30 -4.7%	$43.67 -39.6%	+261.8%	$746.80M	$69.81M	98.35	200
CTKB Cytek Biosciences	2.1184 of 5 stars	$4.19 -0.1%	$5.69 +35.9%	+16.0%	$541.11M	$201.49M	N/A	500	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MASS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

908 Devices (MASS) Competitors

MASS vs. EYPT, TRNS, FEIM, CTKB, and LAB

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Summary

How does 908 Devices compare to Transcat?

Summary

How does 908 Devices compare to Frequency Electronics?

Summary

How does 908 Devices compare to Cytek Biosciences?

Summary

How does 908 Devices compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASS vs. The Competition

908 Devices Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

908 Devices (MASS) Competitors

MASS vs. EYPT, TRNS, FEIM, CTKB, and LAB

How does 908 Devices compare to Eyepoint Pharmaceuticals?

Do analysts prefer EYPT or MASS?

Which has higher valuation and earnings, EYPT or MASS?

Does the media refer more to EYPT or MASS?

Do institutionals and insiders hold more shares of EYPT or MASS?

Which has more risk and volatility, EYPT or MASS?

Is EYPT or MASS more profitable?

Summary

How does 908 Devices compare to Transcat?

Do insiders and institutionals hold more shares of MASS or TRNS?

Is MASS or TRNS more profitable?

Do analysts prefer MASS or TRNS?

Which has more risk and volatility, MASS or TRNS?

Which has higher valuation and earnings, MASS or TRNS?

Does the media refer more to MASS or TRNS?

Summary

How does 908 Devices compare to Frequency Electronics?

Do analysts rate MASS or FEIM?

Which has more volatility and risk, MASS or FEIM?

Is MASS or FEIM more profitable?

Does the media prefer MASS or FEIM?

Do institutionals & insiders have more ownership in MASS or FEIM?

Which has higher valuation & earnings, MASS or FEIM?

Summary

How does 908 Devices compare to Cytek Biosciences?

Does the media refer more to MASS or CTKB?

Is MASS or CTKB more profitable?

Which has more volatility & risk, MASS or CTKB?

Do analysts prefer MASS or CTKB?

Do institutionals and insiders believe in MASS or CTKB?

Which has higher earnings & valuation, MASS or CTKB?

Summary

How does 908 Devices compare to Standard BioTools?

Which has more volatility and risk, MASS or LAB?

Which has higher earnings and valuation, MASS or LAB?

Does the media favor MASS or LAB?

Do analysts prefer MASS or LAB?

Do institutionals & insiders have more ownership in MASS or LAB?

Is MASS or LAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASS vs. The Competition

908 Devices Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools